Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
- PMID: 17183313
- DOI: 10.1038/nature05355
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Abstract
Tumour growth requires accompanying expansion of the host vasculature, with tumour progression often correlated with vascular density. Vascular endothelial growth factor (VEGF) is the best-characterized inducer of tumour angiogenesis. We report that VEGF dynamically regulates tumour endothelial expression of Delta-like ligand 4 (Dll4), which was previously shown to be absolutely required for normal embryonic vascular development. To define Dll4 function in tumour angiogenesis, we manipulated this pathway in murine tumour models using several approaches. Here we show that blockade resulted in markedly increased tumour vascularity, associated with enhanced angiogenic sprouting and branching. Paradoxically, this increased vascularity was non-productive-as shown by poor perfusion and increased hypoxia, and most importantly, by decreased tumour growth-even for tumours resistant to anti-VEGF therapy. Thus, VEGF-induced Dll4 acts as a negative regulator of tumour angiogenesis; its blockade results in a striking uncoupling of tumour growth from vessel density, presenting a novel therapeutic approach even for tumours resistant to anti-VEGF therapies.
Republished in
-
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.Novartis Found Symp. 2007;283:106-20; discussion 121-5, 238-41. Novartis Found Symp. 2007. PMID: 18300417
Comment in
-
Vascular biology: vessel guidance.Nature. 2007 Feb 15;445(7129):722-3. doi: 10.1038/445722a. Nature. 2007. PMID: 17301780 No abstract available.
Similar articles
-
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.Novartis Found Symp. 2007;283:106-20; discussion 121-5, 238-41. Novartis Found Symp. 2007. PMID: 18300417
-
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.Nature. 2006 Dec 21;444(7122):1083-7. doi: 10.1038/nature05313. Nature. 2006. PMID: 17183323
-
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3219-24. doi: 10.1073/pnas.0611206104. Epub 2007 Feb 12. Proc Natl Acad Sci U S A. 2007. PMID: 17296940 Free PMC article.
-
Delta-like 4/Notch signaling and its therapeutic implications.Clin Cancer Res. 2007 Dec 15;13(24):7243-6. doi: 10.1158/1078-0432.CCR-07-1393. Clin Cancer Res. 2007. PMID: 18094402 Review.
-
New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.Biochem Soc Trans. 2011 Dec;39(6):1612-8. doi: 10.1042/BST20110721. Biochem Soc Trans. 2011. PMID: 22103496 Review.
Cited by
-
The complexity of tumour angiogenesis based on recently described molecules.Contemp Oncol (Pozn). 2021;25(1):33-44. doi: 10.5114/wo.2021.105075. Epub 2021 Apr 15. Contemp Oncol (Pozn). 2021. PMID: 33911980 Free PMC article. Review.
-
Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation.Cardiovasc Res. 2016 Jul 1;111(1):84-93. doi: 10.1093/cvr/cvw091. Epub 2016 May 3. Cardiovasc Res. 2016. PMID: 27142980 Free PMC article.
-
Notch signaling in developmental and tumor angiogenesis.Genes Cancer. 2011 Dec;2(12):1106-16. doi: 10.1177/1947601911423030. Genes Cancer. 2011. PMID: 22866202 Free PMC article.
-
Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.Front Cell Dev Biol. 2021 May 28;9:649205. doi: 10.3389/fcell.2021.649205. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34124039 Free PMC article. Review.
-
Notch4 is required for tumor onset and perfusion.Vasc Cell. 2013 Apr 20;5(1):7. doi: 10.1186/2045-824X-5-7. Vasc Cell. 2013. PMID: 23601498 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources